have not been verified as such. One bioinformaticist's "driver mutation" is another's "passenger mutation." Basket studies are a good way of deriving preliminary information on mutations that are potentially responsive in humans to a specific drug -but to design such studies for every potential target mutation, for all possible drugs, in all possible anatomical sites, will be beyond the capacity of our current investigator-and company-initiated system of trials. Plans are under way for larger phase 2 studies such as the National Cancer Institute's Molecular Analysis for Therapy (NCI MATCH) II study, which will enroll about 1000 patients in about 20 mutation-specific groups, but even a larger effort like that one will capture only a small fraction of the targeted therapies being used off-label on the basis of tumor-sequencing data.
Thus, the basket trials are a useful first step in what should be a multistep process. The next step, where feasible, could be larger anatomical-site-specific phase 3 trials comparing the drug-mutation combination with the standard of care. In addition, given the sample-size, logistic, and financial constraints that make phase 3 studies difficult for lesscommon cancers and less-common mutations, establishment of registries of off-label use would be extremely helpful. Aggregated observational data will always be superior to "n of 1" anecdotes or small series. Precedents exist, including the "phase 4" postmarketing surveillance studies that the FDA has mandated in order to gather evidence regarding both possible differences in efficacy for various subgroups and longterm toxicity. Some cancer centers and professional societies are collaborating to develop regional databases. It is critical that results from these databases become as transparent as those from clinical trials -proprietary databases will lead to competing but unverifiable claims. Developing such observational databases is far from trivial, but the costs per patient would be small in relation to the monthly costs of many of the targeted therapies. Perhaps the plural of anecdote could be data after all.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. If we think at all about biotechnology, most of us probably focus on direct threats to human health, such as prospects for converting pathogens to biologic weapons or the implications of new technologies for editing the human germline. But while those debates simmer, the application of biotechnology to agriculture has been rapid and aggressive. The vast majority of the corn and soybeans grown in the United States are now genetically engineered. Foods produced from GM crops have become ubiquitous. And unlike regulatory bodies in 64 other countries, the Food and Drug Administration (FDA) does not require labeling of GM foods.
Two recent developments are dramatically changing the GMO landscape. First, there have been sharp increases in the amounts and numbers of chemical herbicides applied to GM crops, and still further increases -the largest in a generation -are scheduled to occur in the next few years. Second, the International Agency for Research on Cancer (IARC) has classified gly phosate, the herbicide most widely used on GM crops, as a "probable human carcinogen" 1 and classified a second herbicide, 2,4-dichlorophenoxyacetic acid (2,4-D), as a "possible human carcinogen." 2 The application of genetic engineering to agriculture builds 3 Those reviews, which focused almost entirely on the genetic aspects of biotechnology, concluded that GM crops pose no unique hazards to human health. They noted that genetic transformation has the potential to produce unanticipated allergens or toxins and might alter the nutritional quality of food. Both reports recommended development of new risk-assessment tools and postmarketing surveillance. Those recommendations have largely gone unheeded.
Herbicide resistance is the main characteristic that the biotechnology industry has chosen to introduce into plants. Corn and soybeans with genetically engineered tolerance to glyphosate (Roundup) were first introduced in the mid-1990s. These "RoundupReady" crops now account for more than 90% of the corn and soybeans planted in the United States. 4 Their advantage, especially in the first years after introduction, is that they greatly simplify weed management. Farmers can spray herbicide both before and during the growing season, leaving their crops unharmed.
But widespread adoption of herbicide-resistant crops has led to overreliance on herbicides and, in particular, on glyphosate. 5 In the United States, glyphosate use has increased by a factor of more than 250 -from 0.4 million kg in 1974 to 113 million kg in 2014. Global use has increased by a factor of more than 10. Not surprisingly, glyphosate-resistant weeds have emerged and are found today on nearly 100 million acres in 36 states. Fields must be now be treated with multiple herbicides, including 2,4-D, a component of the Agent Orange defoliant used in the Vietnam War.
The first of the two developments that raise fresh concerns about the safety of GM crops is a 2014 decision by the Environmental Protection Agency (EPA) to approve Enlist Duo, a new combination herbicide comprising glyphosate plus 2,4-D. Enlist Duo was formulated to combat herbicide resistance. It will be marketed in tandem with newly approved seeds genetically engineered to resist glyphosate, 2,4-D, and multiple other herbicides. The EPA anticipates that a 3-to-7-fold increase in 2,4-D use will result.
In our view, the science and the risk assessment supporting the Enlist Duo decision are flawed. The science consisted solely of toxicologic studies commissioned by the herbicide manufacturers in the 1980s and 1990s and never published, not an uncommon practice in U.S. pesticide regulation. These studies predated current knowledge of low-dose, endocrine-mediated, and epigenetic effects and were not designed to detect them. The risk assessment gave little consideration to potential health effects in infants and children, thus contravening federal pesticide law. It failed to consider ecologic impact, such as effects on the monarch butterfly and other pollinators. It considered only pure glyphosate, despite studies showing that formulated glyphosate that contains surfactants and adjuvants is more toxic than the pure compound.
The second new development is the determination by the IARC in 2015 that glyphosate is a "probable human carcinogen" 1 and 2,4-D a "possible human carcinogen." 2 These classifications were based on comprehensive assessments of the toxicologic and epidemiologic literature that linked both herbicides to dose-related increases in malignant tumors at multiple anatomical sites in animals and linked glyphosate to an increased incidence of nonHodgkin's lymphoma in humans.
These developments suggest that GM foods and the herbicides applied to them may pose hazards to human health that were not examined in previous assessments. We believe that the time has therefore come to thoroughly reconsider all aspects of the safety of plant biotechnology. The National Academy of Sciences has convened a new committee to reassess the social, economic, environmental, and human health effects of GM crops. This development is welcome, but the committee's report is not expected until at least 2016.
In the meantime, we offer two recommendations. First, we believe the EPA should delay implementation of its decision to permit use of Enlist Duo. This decision was made in haste. It was based on poorly designed and outdated studies and on an incomplete assessment of human exposure and environmental effects. It would have benefited from deeper consideration of independently funded studies published in the peer-reviewed literature.
And it preceded the recent IARC determinations on glyphosate and 2,4-D. Second, the National Toxicology Program should urgently assess the toxicology of pure glyphosate, formulated glyphosate, and mixtures of glyphosate and other herbicides.
Finally, we believe the time has come to revisit the United States' reluctance to label GM foods. Labeling will deliver multiple benefits. It is essential for tracking emergence of novel food allergies and assessing effects of chemical herbicides applied to GM crops. It would respect the wishes of a growing number of consumers who insist they have a right to know what foods they are buying and how they were produced. And the argument that there is nothing new about genetic rearrangement misses the point that GM crops are now the agricultural products most heavily treated with herbicides and that two of these herbicides may pose risks of cancer. We hope, in light of this new information, that the FDA will reconsider labeling of GM foods and couple it with adequately funded, long-term postmarketing surveillance.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. 
